secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-032189
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma Q2 net loss $5.7M ($0.02/sh); signs non-binding MAT2203 term sheet
--------------------------------------------------------------------------------

- Net loss for Q2 2024 was $5.7 million ($0.02 per share), compared to $6.1 million ($0.03) in Q2 2023.
- Cash, cash equivalents and marketable securities were $14.3 million as of June 30, 2024; raised $10M in April offering.
- Signed non-binding term sheet for global licensing rights to develop and commercialize oral MAT2203 for invasive aspergillosis.
- 31 patients enrolled in MAT2203 Compassionate/Expanded Use Access Program; 7 additional under evaluation.
- LNC platform showed tumor inhibition in animal models; additional optimization needed before selecting product candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224032189/0001493152-24-032189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224032189/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer